MA42769B1 - Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 - Google Patents
Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1Info
- Publication number
- MA42769B1 MA42769B1 MA42769A MA42769A MA42769B1 MA 42769 B1 MA42769 B1 MA 42769B1 MA 42769 A MA42769 A MA 42769A MA 42769 A MA42769 A MA 42769A MA 42769 B1 MA42769 B1 MA 42769B1
- Authority
- MA
- Morocco
- Prior art keywords
- muscarinic receptor
- positive allosteric
- allosteric modulators
- compounds
- fluoroindole
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- QISSVLCQDNIJCS-UHFFFAOYSA-N 2-fluoro-1h-indole Chemical class C1=CC=C2NC(F)=CC2=C1 QISSVLCQDNIJCS-UHFFFAOYSA-N 0.000 title 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 abstract 2
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (i), ou des stéréoisomères et sels pharmaceutiquement acceptables en tant que modulateurs allostériques positifs du récepteur muscarinique m1. Cette invention concerne en outre des procédés de fabrication de ces composés et des compositions pharmaceutiques comprenant ces composés. Les composés selon l'invention sont utiles dans le traitement de différents troubles liés au récepteur muscarinique m1.(formule i) (i)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4809CH2015 | 2015-09-10 | ||
| EP16750259.0A EP3347349B1 (fr) | 2015-09-10 | 2016-07-19 | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| PCT/IB2016/054290 WO2017042643A1 (fr) | 2015-09-10 | 2016-07-19 | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42769B1 true MA42769B1 (fr) | 2019-12-31 |
Family
ID=56618200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42769A MA42769B1 (fr) | 2015-09-10 | 2016-07-19 | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10294217B2 (fr) |
| EP (1) | EP3347349B1 (fr) |
| JP (1) | JP6553811B2 (fr) |
| KR (1) | KR102068237B1 (fr) |
| CN (1) | CN108026073B (fr) |
| AU (1) | AU2016320645B2 (fr) |
| BR (1) | BR112018004719B1 (fr) |
| CA (1) | CA2997956C (fr) |
| CY (1) | CY1122321T1 (fr) |
| DK (1) | DK3347349T3 (fr) |
| EA (1) | EA033826B1 (fr) |
| ES (1) | ES2750868T3 (fr) |
| HR (1) | HRP20191869T1 (fr) |
| HU (1) | HUE047056T2 (fr) |
| IL (1) | IL257869A (fr) |
| LT (1) | LT3347349T (fr) |
| MA (1) | MA42769B1 (fr) |
| MD (1) | MD3347349T2 (fr) |
| ME (1) | ME03571B (fr) |
| MX (1) | MX379454B (fr) |
| NZ (1) | NZ740587A (fr) |
| PL (1) | PL3347349T3 (fr) |
| PT (1) | PT3347349T (fr) |
| RS (1) | RS59473B1 (fr) |
| SI (1) | SI3347349T1 (fr) |
| SM (1) | SMT201900608T1 (fr) |
| WO (1) | WO2017042643A1 (fr) |
| ZA (1) | ZA201801463B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438588B1 (ko) | 2017-10-18 | 2022-08-31 | 수벤 라이프 사이언시스 리미티드 | 무스카린 m1 수용체 양성 알로스테릭 조절제로서 헤테로아릴 화합물 |
| MX2020004339A (es) | 2017-10-27 | 2020-08-03 | Suven Life Sciences Ltd | Moduladores alostericos positivos del receptor m1 muscarinico. |
| JP2023512821A (ja) | 2020-02-04 | 2023-03-29 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
| WO2023114224A1 (fr) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda |
| CN115385849B (zh) * | 2022-09-14 | 2024-01-26 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−３−カルボキサミド誘導体 |
| CA2399791A1 (fr) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
| ATE475650T1 (de) | 2005-12-05 | 2010-08-15 | Merck Sharp & Dohme | Positive allosterische chinolon-m1- rezeptormodulatoren |
| RU2507204C2 (ru) * | 2009-08-31 | 2014-02-20 | Мерк Шарп И Доум Корп. | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона |
| HRP20160574T1 (hr) * | 2009-12-17 | 2016-06-17 | Merck Sharp & Dohme Corp. | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida |
| EP2575454B1 (fr) | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Composés de naphthalène carboxamide, modulateurs allostériques positifs du récepteur m1 |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| BR112016006154A2 (pt) | 2013-09-27 | 2017-08-01 | Hoffmann La Roche | derivados de indol e indazol |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| US9708278B2 (en) | 2013-11-27 | 2017-07-18 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1 |
-
2016
- 2016-07-19 PT PT167502590T patent/PT3347349T/pt unknown
- 2016-07-19 DK DK16750259T patent/DK3347349T3/da active
- 2016-07-19 BR BR112018004719-8A patent/BR112018004719B1/pt active IP Right Grant
- 2016-07-19 AU AU2016320645A patent/AU2016320645B2/en active Active
- 2016-07-19 ES ES16750259T patent/ES2750868T3/es active Active
- 2016-07-19 ME MEP-2019-288A patent/ME03571B/fr unknown
- 2016-07-19 HR HRP20191869TT patent/HRP20191869T1/hr unknown
- 2016-07-19 SM SM20190608T patent/SMT201900608T1/it unknown
- 2016-07-19 NZ NZ740587A patent/NZ740587A/en unknown
- 2016-07-19 SI SI201630447T patent/SI3347349T1/sl unknown
- 2016-07-19 PL PL16750259T patent/PL3347349T3/pl unknown
- 2016-07-19 HU HUE16750259A patent/HUE047056T2/hu unknown
- 2016-07-19 LT LT16750259T patent/LT3347349T/lt unknown
- 2016-07-19 RS RS20191328A patent/RS59473B1/sr unknown
- 2016-07-19 MX MX2018002821A patent/MX379454B/es unknown
- 2016-07-19 CN CN201680052764.2A patent/CN108026073B/zh active Active
- 2016-07-19 JP JP2018512868A patent/JP6553811B2/ja active Active
- 2016-07-19 MD MDE20180689 patent/MD3347349T2/ro unknown
- 2016-07-19 EA EA201890684A patent/EA033826B1/ru unknown
- 2016-07-19 WO PCT/IB2016/054290 patent/WO2017042643A1/fr not_active Ceased
- 2016-07-19 EP EP16750259.0A patent/EP3347349B1/fr active Active
- 2016-07-19 KR KR1020187009938A patent/KR102068237B1/ko active Active
- 2016-07-19 US US15/758,313 patent/US10294217B2/en active Active
- 2016-07-19 MA MA42769A patent/MA42769B1/fr unknown
- 2016-07-19 CA CA2997956A patent/CA2997956C/fr active Active
-
2018
- 2018-03-02 ZA ZA2018/01463A patent/ZA201801463B/en unknown
- 2018-03-05 IL IL257869A patent/IL257869A/en active IP Right Grant
-
2019
- 2019-10-16 CY CY20191101086T patent/CY1122321T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA45153B1 (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA49235B1 (fr) | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
| MA56674B1 (fr) | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA35833B1 (fr) | Dérivés de bétuline | |
| MA40523B1 (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA40769B1 (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA39983B1 (fr) | Dérivés de carboxamide |